Efficacy and safety of radiotherapy in patients with microsatellite stable or proficient mismatch repair colorectal cancer liver metastasis

Table 1 Baseline data comparison, n (%)

	Control (n = 21)	Observation (n = 22)	t/χ2	P value
Gender			1.122	0.289
Male	11 (52.38)	15 (68.18)
Female	10 (47.62)	7 (31.82)
Age, years	58.39 ± 6.47	59.16 ± 5.82	0.410	0.683
BMI, kg/m2	22.98 ± 2.31	22.67 ± 2.29	0.441	0.660
Condition			0.003	0.955
Left	18 (85.71)	20 (90.91)
Right	3 (14.29)	2 (9.09)
RAS mutation status			0.617	0.432
Wild type	10 (47.62)	7 (31.82)
Mutated	8 (38.10)	11 (50.00)
Not tested	3 (14.29)	4 (18.18)
Other metastatic sites
Lung metastasis	16 (76.19)	13 (59.09)	1.430	0.231
Lymph node metastasis	13 (61.90)	16 (72.73)	0.573	0.449
Bone metastasis	3 (14.29)	5 (22.73)	0.101	0.749
Peritoneal metastasis	4 (19.05)	4 (18.18)	0.101	0.749
Other	11 (52.38)	10 (45.45)	0.206	0.649
TKI used			2.117	0.145
Regorafenib	8 (38.10)	4 (18.18)
Fruquintinib	13 (61.90)	18 (81.82)

BMI: Body mass index; TKI: Tyrosine kinase inhibitor.

Table 2 Comparison of treatment efficacy, n (%)

	Control (n = 21)	Observation (n = 22)	χ2	P value
CR	0 (0.00)	0 (0.00)
PR	1 (4.76)	3 (13.64)
SD	4 (19.05)	11 (50.00)
PD	16 (76.19)	8 (36.36)
ORR	1 (4.76)	3 (13.64)	0.226	0.633
DCR	5 (23.81)	14 (63.64)	6.910	0.008

CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; ORR: Objective response rate; DCR: Disease control rate.

Table 3 Comparison of adverse reaction incidence, n (%)

Adverse reaction	Control (n = 21)	Observation (n = 22)	χ2	P value
Nausea and vomiting	8 (38.10)	6 (27.27)	0.573	0.449
Gastrointestinal reaction	5 (23.81)	4 (18.18)	0.006	0.937
Skin reaction	3 (14.29)	4 (18.18)	0.004	0.946
Bone marrow suppression	4 (19.05)	5 (22.73)	0.006	0.937
Liver and kidney function damage	13 (61.90)	11 (50.00)	0.617	0.432
Neurotoxicity	2 (9.52)	4 (18.18)	0.143	0.704
Leukopenia	8 (38.10)	7 (31.82)	0.186	0.665
Neutropenia	5 (23.81)	6 (27.27)	0.067	0.794
Thrombocytopenia	6 (28.57)	7 (31.82)	0.053	0.816